Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Ozempic (semaglutide) and Tresiba (insulin degludec) are both injectable medications used to manage diabetes, but they work differently and have different uses. Ozempic is a GLP-1 agonist that helps lower blood sugar by increasing insulin release, reducing sugar production in the liver, and slowing digestion. It is used for Type 2 diabetes and also helps lower the risk of heart problems in people with Type 2 diabetes and heart disease. Insulin degludec, on the other hand, is a long-acting insulin that helps control blood sugar levels in both Type 1 and Type 2 diabetes. Ozempic is injected once a week, while insulin degludec is injected once daily. Ozempic can cause side effects like nausea, vomiting, and diarrhea, whereas insulin degludec can cause low blood sugar, weight gain, and injection site reactions. Additionally, Ozempic is available only as a brand-name medication, while insulin degludec is available as a lower-cost generic.
Ozempic (semaglutide)
Insulin degludec (Tresiba)
Ozempic (semaglutide)
Insulin degludec (Tresiba)
Summary of Ozempic vs. Tresiba
Summary for GLP-1 agonist
Prescription only
Ozempic (semaglutide) is a GLP-1 agonist used with diet and exercise to help adults manage Type 2 diabetes. It can also lower the risk of heart attack, stroke, and heart-related death in some people with Type 2 diabetes. It comes as a once-weekly injection under the skin and as a tablet taken by mouth once a day. The injection is also approved to help slow worsening kidney problems in people with Type 2 diabetes and chronic kidney disease (CKD). Common side effects include nausea, vomiting, and diarrhea.